CGIH20014, Dunne, EA2187, Cholangiocarcino, Pevonedistat, Carboplatin, Paclitaxel
Basic Study Information
Purpose:
This phase II trial studies how well pevonedistat alone or in combination with chemotherapy
(paclitaxel and carboplatin) works in treating patients with bile duct cancer of the
liver. Pevonedistat may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth. Drugs used in chemotherapy, such as paclitaxel and carboplatin,
work in different ways to stop the growth of tumor cells, either by killing the cells,
by stopping them from dividing, or by stopping them from spreading. This study may
help the study doctors find out how well pevonedistat shrinks bile duct cancer of
the liver when given alone and when in combination with paclitaxel and carboplatin.
Location: University of Rochester
Lead Researcher (Principal Investigator)
Lead Researcher:
Richard Dunne
Study Contact Information
Study Coordinator: Tina Bowdish
Phone: +1 585-275-9475
Email: tina_bowdish@urmc.rochester.edu
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search